Of the submissions that we heard that addressed the bill, we were reassured that some of the issues that we have grappled with they were comfortable with, and many of them are much greater experts than we are in this domain. More particularly, we were reassured by their assay of the international evidence—which, in the absence of the Pfizer application to Medsafe, which they wrote to us saying it would be in the coming months—that suggests that there are more benefits to proceeding now rather than waiting for that application to Medsafe. So here in the second reading, it has an assessment of what the select committee did. National will be continuing to support this bill in the committee of the whole House. There will be a few points that we'll just raise for discussion, but here in the second reading we are supporting this bill. Thank you, Madam Speaker.